Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Amlexanox and NAD+ — mechanism, dosing, side effects, legal status, and pricing.
Amlexanox is a non-peptide small-molecule 2-amino-chromeno[2,3-b]pyridine-3-carboxylic acid derivative (CAS 68302-57-8, MW 298.29 g/mol). Originally approved in 1996 as a topical oral paste for aphthous ulcers (FDA, now discontinued) and in Japan for allergic conditions, it was later characterized as a selective ATP-competitive inhibitor of the non-canonical IκB kinases TBK1 and IKKε. It is NOT approved for any metabolic, obesity, or performance indication; it is sold by research-chemical vendors labeled research-use-only and promoted off-label by biohacking outlets for fat loss. No validated human dose exists for metabolic applications.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells, not a peptide. It is classified here alongside peptides for user convenience in the anti-aging / metabolic category. NAD+ plays a central role in cellular energy metabolism and redox reactions and is studied for its involvement in mitochondrial function, DNA-damage signaling via sirtuins and PARPs, and age-associated metabolic decline. IV NAD+ is not FDA-approved for any clinical indication; it is administered off-label through compounding pharmacies and functional-medicine clinics with limited rigorous outcome data.
Amlexanox
NAD+
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Amlexanox
NAD+
COA corpus from Disclosed Labs — independently tested batches only.
Amlexanox
1
COAs
99.6%
Avg purity
1
Labs
NAD+
146
COAs
99.4%
Avg purity
15
Labs
In diet-induced obese and ob/ob mice, amlexanox treatment increased energy expenditure via thermogenesis, produced weight loss, improved insulin sensitivity, and decreased hepatic steatosis; these metabolic benefits require intact FGF21 signaling. In LDL-receptor-knockout mice on Western diet, amlexanox reduced triglycerides, cholesterol, circulating monocytes/eosinophils, macrophage plaque accumulation, and atherosclerotic lesion size. One randomized, double-blind, placebo-controlled proof-of-concept trial in 42 obese patients with type 2 diabetes and NAFLD showed statistically significant HbA1c and fructosamine reductions versus placebo, with a responder subgroup showing improved insulin sensitivity and reduced hepatic fat; rash occurred in several participants (two required biopsy). No obesity or diabetes indication has been approved by any regulator.
The strongest human evidence for raising circulating NAD+ comes from oral-precursor trials. A randomized, double-blind, placebo-controlled study of nicotinamide riboside combined with pterostilbene (NRPT) showed sustained dose-dependent increases in whole-blood NAD+ over 8 weeks in healthy adults (Dellinger et al., npj Aging and Mechanisms of Disease, 2017). A Yoshino/Baur/Imai review summarizes the biology and emerging therapeutic potential of NR and NMN, including preclinical healthspan data in aged mice (Cell Metabolism, 2018). Direct IV NAD+ has only small pilot pharmacokinetic data: Grant et al. infused 750 mg over 6 hours in 8 healthy men and documented altered plasma and urine NAD+ metabolome without clinical-outcome endpoints (Frontiers in Aging Neuroscience, 2019). No adequately powered RCTs support IV or SubQ NAD+ for anti-aging, cognition, addiction, or Parkinson's disease; clinic marketing claims outrun the published outcome evidence.
Amlexanox and NAD+ are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Key references
Disclosed Labs